All patients
age >= 65 yr omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
neutralizing antibody in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ITAC, 2022 0.80 [0.42; 1.52]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.78 [0.69 ; 0.88 ] ITAC, 2022, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 0% 4,929 moderate not evaluable death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ITAC, 2022 0.80 [0.42; 1.52]
Lopardo, 2021 0.57 [0.24; 1.37]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.78 [0.70 ; 0.87 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 2021, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 7 0% 7,268 moderate not evaluable deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
0.74 [0.55 ; 1.01 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022 2 0% 1,784 moderate not evaluable clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
Lopardo, 2021 1.61 [0.75; 3.49]
1.07 [0.97 ; 1.18 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 2021 4 0% 2,557 moderate not evaluable clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
0.98 [0.76 ; 1.26 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022 2 0% 899 moderate not evaluable death or ventilationdetailed results RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.79 [0.65 ; 0.95 ] RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 34% 4,280 moderate not evaluable hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.16 [0.97 ; 1.39 ] ACTIV-3/TICO LY-CoV555 , 2020, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 58% 4,664 moderate not evaluable ICU admissiondetailed results Lopardo, 2021 0.67 [0.35; 1.28]
0.67 [0.35 ; 1.28 ] Lopardo, 2021 1 0% 241 NA not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
1.09 [0.96 ; 1.25 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020 3 0% 1,028 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable serious adverse eventsdetailed results ITAC, 2022 0.98 [0.66; 1.46]
0.98 [0.66 ; 1.46 ] ITAC, 2022 1 0% 579 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:41 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 729,887,742,878,975,570,771,888,1141,690,880,1255
- roots T: 290
